Home » Authors » Brady Huggett

Articles by Brady Huggett

$43.9M Series C Gives XenoPort Active Transport Program Funds

June 4, 2002

By Brady Huggett

XenoPort Inc. came off the financing trail with a $43.9 million Series C under it arm - its largest round to date. (BioWorld Today)

Agennix Raises $20M Privately, Prepares For Clinical Explosion

May 31, 2002

By Brady Huggett

Agennix Raises $20M Privately, Prepares For Clinical Explosion

May 31, 2002

By Brady Huggett

Paratek Raises $30M In Series D To Move First Product Into Clinic

May 29, 2002

By Brady Huggett

Paratek Raises $30M In Series D To Move First Product Into Clinic

May 29, 2002

By Brady Huggett

GlycoDesign Ends GD0039 Trials, Moving Focus To Other Programs

May 28, 2002

By Brady Huggett

GlycoDesign Ends GD0039 Trials, Moving Focus To Other Programs

May 28, 2002

By Brady Huggett

UTC's Remodulin Approved; Product Hits Market Running

May 24, 2002

By Brady Huggett

UTC's Remodulin Approved; Product Hits Market Running

May 24, 2002

By Brady Huggett

Biogen's Amevive Before Panel Today; FDA Hints At New Trials

May 23, 2002

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.